Genetic Basis of Cancer

Genetic Basis of Cancer

Genetic Basis of Cancer

On this page

Cancer Genes - The Prime Suspects

  • Proto-oncogenes (Accelerators):
    • Promote normal cell growth/division.
    • Mutation (gain-of-function) → Oncogenes (e.g., RAS, MYC, EGFR).
  • Tumor Suppressor Genes (TSGs) (Brakes):
    • Inhibit proliferation, induce apoptosis.
    • Mutation (loss-of-function, Knudson's "two-hit" hypothesis).
    • E.g., TP53, RB1, APC, BRCA1/2.
  • Apoptosis Regulating Genes:
    • Control programmed cell death.
    • Imbalance (e.g., ↑BCL-2 anti-apoptotic, ↓BAX pro-apoptotic) → uncontrolled cell survival.
  • DNA Repair Genes (Caretakers):
    • Maintain genomic integrity.
    • Defects → ↑mutation rates, genomic instability (e.g., MSH2, MLH1, BRCA).

TP53, "guardian of the genome," is the most commonly mutated gene, found in >50% of sporadic human cancers.

Oncogenes - Pedal to Metal

  • Mutated or overexpressed versions of normal proto-oncogenes; they drive uncontrolled cell proliferation via gain-of-function mutations.
  • Dominant: one mutated allele sufficient.
  • Activation Mechanisms:
    • Point Mutation: RAS (pancreatic, colon, lung Ca).
    • Gene Amplification: N-MYC (neuroblastoma), ERBB2/HER2 (breast Ca).
    • Chromosomal Translocation:
      • BCR-ABL (t(9;22), Philadelphia chr.): CML.
      • MYC (t(8;14)): Burkitt lymphoma.
  • Examples & Roles:
    • RAS: GTP-binding protein, signal transduction.
    • MYC: Transcription factor, cell cycle progression.
    • ERBB2 (HER2): Receptor tyrosine kinase.
    • ABL: Non-receptor tyrosine kinase.

BCR-ABL fusion in CML results in constitutively active tyrosine kinase, a prime target for imatinib. Oncogene Activation Mechanisms

Tumor Suppressors - Guardians Down!

  • Act as cellular "brakes"; normally prevent uncontrolled cell growth.
  • Loss-of-function mutations promote cancer.
  • Typically require inactivation of both alleles (Knudson's "two-hit" hypothesis).
    • First hit: often germline (inherited).
    • Second hit: somatic (acquired).
  • Key Examples & Associations:
    • RB1: Retinoblastoma, osteosarcoma (G1/S checkpoint).
    • TP53: Li-Fraumeni syndrome ("Guardian of the Genome").
    • APC: Familial adenomatous polyposis (FAP), colorectal cancer.
    • BRCA1/BRCA2: Hereditary breast and ovarian cancer.
    • NF1/NF2: Neurofibromatosis 1 & 2.
    • WT1: Wilms tumor. Knudson Two-Hit Hypothesis: Hereditary vs. Non-Hereditary

TP53 is the most frequently mutated gene in human cancers, implicated in over 50% of sporadic tumors.

System Sabotage - Repair, Death, Epigenetics

  • DNA Repair Defects (Genomic Instability):
    • Mismatch Repair (MMR): HNPCC/Lynch (MSH2, MLH1). Microsatellite Instability (MSI).
    • Nucleotide Excision Repair (NER): Xeroderma Pigmentosum (XP). UV sensitivity, skin cancers.
    • Homologous Recombination (HR): BRCA1/2 mutations. Breast, ovarian cancer risk. Fanconi Anemia.
    • ATM gene: Ataxia-Telangiectasia. Defective DNA damage sensing.
  • Evasion of Apoptosis (Resisting Cell Death):
    • BCL-2 family: ↑Anti-apoptotic BCL-2 (follicular lymphoma t(14;18)).
    • TP53 mutations: Loss of p53-mediated apoptosis.
    • IAPs: Upregulation blocks caspases.
  • Epigenetic Alterations (Gene expression changes without DNA sequence alteration):
    • DNA Methylation: TSG promoter hypermethylation (CDKN2A, MLH1). Global hypomethylation.
    • Histone Modification: Altered acetylation, methylation (EZH2).
    • Non-coding RNAs: Dysregulated miRNAs (oncomiRs) & lncRNAs.

⭐ Follicular Lymphoma's t(14;18) translocation constitutively activates BCL-2 by placing it near the IgH enhancer, promoting cell survival via apoptosis evasion.

High‑Yield Points - ⚡ Biggest Takeaways

  • Proto-oncogenes (e.g., RAS, MYC) drive cancer via gain-of-function mutations.
  • Tumor suppressor genes (e.g., TP53, RB1) require loss-of-function (Knudson's two-hit hypothesis).
  • TP53 is the most commonly mutated gene in human cancers, crucial for cell cycle control.
  • Defects in DNA repair genes (e.g., BRCA1/2, MSH/MLH) lead to ↑ genomic instability.
  • Epigenetic alterations like hypermethylation can silence tumor suppressor genes.
  • Chromosomal translocations (e.g., BCR-ABL in CML) create oncogenic fusion proteins.
  • Telomerase reactivation allows limitless replicative potential, a hallmark of cancer.

Practice Questions: Genetic Basis of Cancer

Test your understanding with these related questions

A boy presents with fever, night sweats, and neck swelling. The biopsy of swelling showed a starry sky appearance. What is the most likely genetic abnormality seen in this case?

1 of 5

Flashcards: Genetic Basis of Cancer

1/10

ER/PR-_____, HER2-negative cancers is the most common subtype of breast cancer in individuals who inherit germline mutations in BRCA2

TAP TO REVEAL ANSWER

ER/PR-_____, HER2-negative cancers is the most common subtype of breast cancer in individuals who inherit germline mutations in BRCA2

positive

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial